May 2023 in “Journal of contemporary medicine” This study observed that patients who received Favipiravir treatment after having COVID-19 had lower positive pull test scores for telogen effluvium hair loss compared to those who did not, suggesting that Favipiravir may not influence the development of telogen effluvium.
April 2024 in “Public health” In this study of non-hospitalized patients in Dubai, pre-COVID vaccination and treatments with favipiravir or sotrovimab were associated with a reduced risk of developing long COVID.
51 citations
,
August 2021 in “Turkish Journal of Medical Sciences” This review concluded that monoclonal antibodies are currently the most effective treatment for COVID-19, with potential efficacy of high-titer convalescent plasma when used early, while multiple other drugs require further evaluation to determine their effectiveness.
8 citations
,
August 2022 in “Microorganisms” This study reports that drug repurposing for COVID-19 has had mixed results, with success for some drugs but a lack of clinical efficacy for others, highlighting the need for improved preclinical profiling and a standardized drug development platform for future antiviral treatments.
6 citations
,
March 2022 in “Frontiers in drug discovery” This review summarizes 25 small molecule drugs with in vitro and in vivo data for COVID-19 treatment, highlighting their structural diversity and potential to guide future antiviral discovery.